Arthneeti
All Q2 FY27 results →
TT

Thyrocare Technologies Ltd

Q2 FY27Healthcare Services

Thyrocare Technologies Q2 Results 2026 (FY27) investor presentation: Revenue & Margins

Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.

Price₹495
Market cap₹7.9K Cr
P/E43.6
Updated29 Oct 2026
Read4 min read

Thyrocare Technologies Ltd Q2 FY27 key numbers

Revenue
Q2 FY27 revenue from operations (Consolidated): INR 270.8 crore, +25.1% YoY.

As stated in Thyrocare Technologies Ltd's Q2 FY27 investor presentation · published 29 Oct 2026. Reported figures, not investment advice.

Based on Thyrocare Technologies Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

The short version

Q2 FY27 revenue from operations (Consolidated): INR 270.8 crore, +25.1% YoY (Page 30, 26, 19) - TTL Standalone Q2 FY27 revenue: INR 256.3 crore, +26.8% YoY (Page 24) - Radiology business revenue Q2 FY27: INR 13.6 crore, -4.2% YoY (Page 25) - Quarterly active franchisees: 12,911 in Q2 FY27, +32% CAGR over 5 years (Page 22) - Tests conducted: 61.6 million in Q2 FY27, +27% YoY (Page 11, 23) - Patients: 5.7 million in Q2 FY27, +14% YoY (Page 11, 21) - Revenue per test and revenue per patient both grew ~10% over 2 years (Page 21) - Q2 FY27 EBITDA: INR 89.3 crore (Consolidated), up 25.0% YoY - EBITDA Margin: 33.0%, consistent with Q2 FY26 (33.0%) - Reported PAT: INR 15.2 crore, lower due to exceptional items - PAT before exceptions: INR 60.2 crore, up 25.7% YoY - PAT Margin before exceptions: 22.2% (Q2 FY27) vs 22.1% (Q2 FY26) - Revenue Growth: 25.1% YoY to INR 270.8 crore

From Thyrocare Technologies Ltd's Q2 FY27 earnings-call transcript · updated 29 Oct 2026.

Revenue & Sales Performance

  • Q2 FY27 revenue from operations (Consolidated): INR 270.8 crore, +25.1% YoY (Page 30, 26, 19)
  • TTL Standalone Q2 FY27 revenue: INR 256.3 crore, +26.8% YoY (Page 24)
  • Radiology business revenue Q2 FY27: INR 13.6 crore, -4.2% YoY (Page 25)
  • Quarterly active franchisees: 12,911 in Q2 FY27, +32% CAGR over 5 years (Page 22)
  • Tests conducted: 61.6 million in Q2 FY27, +27% YoY (Page 11, 23)
  • Patients: 5.7 million in Q2 FY27, +14% YoY (Page 11, 21)

2 more points from Thyrocare Technologies Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Thyrocare Technologies Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Capex invested: INR 33.2 crore in H1FY27
  • Purpose: 8 new lab expansions and additions of new machines for capacity enhancement
  • Status: Completed in H1FY27 (first half of FY 2027)
  • Expansion into specialty diagnostics and institutional partnerships noted as growth pillars, but without specific capex or timeline figures

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
1Health X Platform
Rev 1Mar 1
2Chandan Healthca
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 2
5
Rev 2Mar 2
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Thyrocare Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Thyrocare Technologies Ltd said on order book & pipeline — free account, 30 seconds.

Thyrocare Technologies Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹271 Cr, net profit ₹15 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Thyrocare Tech.'s management said in earlier quarters

Others in Healthcare Services this season

  • Rainbow Childrens Medicare Ltd (Q2 FY27)

    Year-on-year (YoY) growth in revenue: 23.2% . Key investor presentation takeaways from Rainbow Childrens Medicare Ltd's Q2 FY27 investor presentation — and how

  • Narayana Hrudayalaya Ltd (Q2 FY27)

    Consolidated operating revenue for Q2 FY27: ₹28,440 Mn, up 73.0% YoY (Page 15, 16). Key investor presentation takeaways from Narayana Hrudayalaya Ltd's Q2 FY27

  • Artemis Medicare Services Ltd (Q2 FY27)

    Q2 FY27 consolidated revenue from operations: INR 31,104 Lacs, up 13.2% YoY (Page 39, 40, 20). Key investor presentation takeaways from Artemis Medicare Service

  • Max Healthcare Institute Ltd (Q2 FY27)

    Q2 FY27 Gross Revenue: ₹3,219 Cr, up 20% YoY (Page 4, 17) . Key investor presentation takeaways from Max Healthcare Institute Ltd's Q2 FY27 investor presentatio

Compare:vs Apollo Hospitals Enterprise Ltdvs Manipal Health Enterprises Ltdvs Max Healthcare Institute Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Thyrocare Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Thyrocare Technologies Ltd Q2 FY27 results?

Q2 FY27 revenue from operations (Consolidated): INR 270.8 crore, +25.1% YoY (Page 30, 26, 19) - TTL Standalone Q2 FY27 revenue: INR 256.3 crore, +26.8% YoY (Page 24) - Radiology business revenue Q2 FY27: INR 13.6 crore, -4.2% YoY (Page 25) - Quarterly active franchisees: 12,911 in Q2 FY27, +32% CAGR over 5 years (Page 22) - Tests conducted: 61.6 million in Q2 FY27, +27% YoY (Page 11, 23) - Patients: 5.7 million in Q2 FY27, +14% YoY (Page 11, 21) - Revenue per test and revenue per patient both grew ~10% over 2 years (Page 21) - Q2 FY27 EBITDA: INR 89.3 crore (Consolidated), up 25.0% YoY - EBITDA Margin: 33.0%, consistent with Q2 FY26 (33.0%) - Reported PAT: INR 15.2 crore, lower due to exceptional items - PAT before exceptions: INR 60.2 crore, up 25.7% YoY - PAT Margin before exceptions: 22.2% (Q2 FY27) vs 22.1% (Q2 FY26) - Revenue Growth: 25.1% YoY to INR 270.8 crore

What is Thyrocare Technologies Ltd share price analysis?

Thyrocare Technologies Ltd currently shows a neutral. The stock trades at a P/E of 43.5 with a market cap of ₹7,871 Cr. Investors should review the full earnings analysis for detailed insights.

Is Thyrocare Technologies Ltd planning capital expenditure?

Capex invested: INR 33.2 crore in H1FY27 - Purpose: 8 new lab expansions and additions of new machines for capacity enhancement - Status: Completed in H1FY27 (first half of FY 2027) - No explici

Keep Thyrocare Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.